A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously. Twelve pigs (n = 6/intervention) were euthanized one day post-injection, while the remaining twelve pigs were euthanized seven days post-injection (n = 6/intervention). We performed autoradiography on hippocampus and prefrontal cortex (PFC) sections with [3H]UCB-J (SV2A), [3H]MDL100907 (5-HT2AR antagonist) and [3H]Cimbi-36 (5-HT2AR agonist). One day post psilocybin injection, we observed 4.42% higher hippocampal SV2A density and lowered hippocampal and PFC 5-HT2AR density (−15.21% to −50.19%). These differences were statistically significant in the hippocampus for all radioligands and in the PFC for [3H]Cimbi-36 only. Seven days post-intervention, there was still significantly higher SV2A density in the hippocampus (+9.24%) and the PFC (+6.10%), whereas there were no longer any differences in 5-HT2AR density. Our findings suggest that psilocybin causes increased persistent synaptogenesis and an acute decrease in 5-HT2AR density, which may play a role in psilocybin’s antidepressive effects.

[1]  G. Knudsen,et al.  Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig , 2020, European Neuropsychopharmacology.

[2]  M. Liechti,et al.  Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers , 2020, ACS pharmacology & translational science.

[3]  Matthew W. Johnson,et al.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder , 2020, JAMA psychiatry.

[4]  J. Riba,et al.  N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo , 2020, Translational Psychiatry.

[5]  F. Vollenweider,et al.  Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders , 2020, Nature Reviews Neuroscience.

[6]  C. Halldin,et al.  Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain. , 2020, Synapse.

[7]  Sara Marmolejo-Martínez-Artesero,et al.  Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins , 2019, European Neuropsychopharmacology.

[8]  D. Val-Laillet,et al.  Validation of a Psychosocial Chronic Stress Model in the Pig Using a Multidisciplinary Approach at the Gut-Brain and Behavior Levels , 2019, Front. Behav. Neurosci..

[9]  K. Blennow,et al.  Synaptic vesicle protein 2A as a potential biomarker in synaptopathies , 2019, Molecular and Cellular Neuroscience.

[10]  Dustin Scheinost,et al.  Lower synaptic density is associated with depression severity and network alterations , 2019, Nature Communications.

[11]  C. Svarer,et al.  Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels , 2019, Neuropsychopharmacology.

[12]  Kwang H. Choi,et al.  Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in the prefrontal cortex, amygdala, and hippocampus of Sprague-Dawley rats , 2019, IBRO reports.

[13]  A. van Waarde,et al.  Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging , 2018, Medicinal research reviews.

[14]  D. E. Olson,et al.  Psychedelics Promote Structural and Functional Neural Plasticity , 2018, Cell reports.

[15]  A. Feilding,et al.  The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro , 2017, Scientific Reports.

[16]  R. Franzen,et al.  Puzzling Out Synaptic Vesicle 2 Family Members Functions , 2017, Front. Mol. Neurosci..

[17]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[18]  B. Schmidt,et al.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.

[19]  M. Liechti,et al.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.

[20]  D. Spencer,et al.  Imaging synaptic density in the living human brain , 2016, Science Translational Medicine.

[21]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[22]  Claus Svarer,et al.  Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin , 2016, NeuroImage.

[23]  Claus Svarer,et al.  A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System , 2017, The Journal of Neuroscience.

[24]  Gitte Moos Knudsen,et al.  Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain , 2014, NeuroImage.

[25]  J. González-Maeso,et al.  P.1.g.022 Hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists induce distinct patterns of G protein coupling in postmortem human brain , 2013, European Neuropsychopharmacology.

[26]  J. Palacios,et al.  Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI , 2013, Experimental Brain Research.

[27]  M. Banasr,et al.  Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. , 2013, The international journal of neuropsychopharmacology.

[28]  Claus Svarer,et al.  Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36 , 2013, Molecular Imaging and Biology.

[29]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[30]  G. Rajkowska,et al.  Decreased Expression of Synapse-Related Genes and Loss of Synapses in Major Depressive Disorder , 2012, Nature Medicine.

[31]  Amy L. Nowack,et al.  SV2 regulates neurotransmitter release via multiple mechanisms. , 2010, American journal of physiology. Cell physiology.

[32]  Michael Kometer,et al.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.

[33]  G. Réus,et al.  Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus , 2010, Journal of neural transmission.

[34]  Ryan T. Strachan,et al.  Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling , 2009, Proceedings of the National Academy of Sciences.

[35]  D. Hanniford,et al.  Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes. , 2005, Assay and drug development technologies.

[36]  Bryan L Roth,et al.  Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists , 2001, Brain Research Bulletin.

[37]  M. Loza,et al.  Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. , 2001, Molecular pharmacology.

[38]  V. Watts,et al.  Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. , 2000, Journal of medicinal chemistry.

[39]  J. Hensler,et al.  Regulation of 5-HT2A receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin , 2000, Neuropharmacology.

[40]  Donatella Marazziti,et al.  Distribution and characterization of [3H]mesulergine binding in human brain postmortem , 1999, European Neuropsychopharmacology.

[41]  B. Roth,et al.  Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. , 1996, Molecular pharmacology.

[42]  M. Pompeiano,et al.  Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. , 1994, Brain research. Molecular brain research.

[43]  D. X. Freedman,et al.  Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. , 1988, Life sciences.

[44]  R. Lefkowitz,et al.  A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. , 1980, Molecular pharmacology.

[45]  R. Mowbray,et al.  HALLUCINOGENS , 1970, The Medical journal of Australia.